# 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours

> **NCT06155994** · PHASE1,PHASE2 · COMPLETED · sponsor: **Medical University Innsbruck** · enrollment: 12 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** 68Ga-DOTA-MGS5

## Key facts

- **NCT ID:** NCT06155994
- **Lead sponsor:** Medical University Innsbruck
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-20
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06155994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06155994, "68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06155994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*